Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Contineum Therapeutics, Inc. (CTNM) had Normalized Income after Taxes of $-15.15M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-15.15M |
|
-- |
|
-- |
|
$17.43M |
|
$-17.43M |
|
$2.27M |
|
$-15.15M |
|
$-15.15M |
|
$-15.15M |
|
$-15.15M |
|
$-15.15M |
|
|
Normalized Income after Taxes |
$-15.15M |
$-17.43M |
|
$-17.29M |
|
37.47M |
|
37.47M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$242.58M |
|
$0.93M |
|
$7.79M |
|
$250.37M |
|
$6.53M |
|
-- |
|
$4.18M |
|
$10.71M |
|
$239.66M |
|
$239.66M |
|
$239.66M |
|
37.61M |
|
| Cash Flow Statement Financials | |
$-27.77M |
|
$-34.45M |
|
$1.33M |
|
$75.60M |
|
$14.71M |
|
$-60.89M |
|
$7.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
37.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.32% |
|
-6.32% |
|
-6.05% |
|
-6.32% |
|
$6.37 |
|
$-0.75 |
|
$-0.74 |
|